Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004238966> ?p ?o ?g. }
- W2004238966 abstract "When treating schizophrenia, improving patients' productivity level is a major goal considering schizophrenia is a leading cause of functional disability. Productivity level has been identified as the most preferred treatment outcome by patients with schizophrenia. However, little has been done to systematically investigate productivity levels in schizophrenia. We set out to better understand the change in productivity level among chronically ill patients with schizophrenia treated with olanzapine compared with other antipsychotic medications. We also assessed the links between productivity level and other clinical outcomes. This post hoc analysis used data from 6 randomized, double-blind clinical trials of patients with schizophrenia or schizoaffective disorder, with each trial being of approximately 6 months duration. Change in productivity level was compared between olanzapine-treated patients (HGBG, n = 172; HGHJ, n = 277; HGJB, n = 171; HGLB, n = 281; HGGN, n = 159; HGDH, n = 131) and patients treated with other antipsychotic medications (separately vs. haloperidol [HGGN, n = 97; HGDH, n = 132], risperidone [HGBG, n = 167; HGGN, n = 158], quetiapine [HGJB, n = 175], ziprasidone [HGHJ, n = 271] and aripiprazole [HGLB, n = 285]). Productivity was defined as functional activities/work including working for pay, studying, housekeeping and volunteer work. Productivity level in the prior 3 months was assessed on a 5-point scale ranging from no useful functioning to functional activity/work 75% to 100% of the time. Chronically ill patients treated with olanzapine (OLZ) experienced significantly greater improvement in productivity when compared to patients treated with risperidone (RISP) (OLZ = 0.22 ± 1.19, RISP = -0.03 ± 1.17, p = 0.033) or ziprasidone (ZIP) (OLZ = 0.50 ± 1.38, ZIP = 0.25 ± 1.27, p = 0.026), but did not significantly differ from the quetiapine, aripiprazole or haloperidol treatment groups. Among first episode patients, OLZ therapy was associated with greater improvements in productivity levels compared to haloperidol (HAL), during the acute phase (OLZ = -0.31 ± 1.59, HAL = -0.69 ± 1.56, p = 0.011) and over the long-term (OLZ = 0.10 ± 1.50, HAL = -0.32 ± 1.91, p = 0.008). Significantly more chronically ill and first episode patients treated with olanzapine showed moderately high (>50%-75% of the time) and high levels of productivity (>75%-100% of the time) at endpoint, when compared to risperidone or haloperidol-treated patients (p < .05), respectively. Higher productivity level was associated with significantly higher study completion rates and better scores on the positive, negative, disorganized thoughts, hostility and depression subscales of the Positive and Negative Symptom Scale (PANSS). Some antipsychotic medications significantly differed in beneficial impact on productivity level in the long-term treatment of patients with schizophrenia. Findings further highlight the link between clinical and functional outcomes, showing significant associations between higher productivity, lower symptom severity and better persistence on therapy. clinicaltrials.gov identifier NCT00088049 ; NCT00036088" @default.
- W2004238966 created "2016-06-24" @default.
- W2004238966 creator A5011706362 @default.
- W2004238966 creator A5024756328 @default.
- W2004238966 creator A5042279631 @default.
- W2004238966 creator A5085051732 @default.
- W2004238966 creator A5086273186 @default.
- W2004238966 date "2011-05-17" @default.
- W2004238966 modified "2023-09-26" @default.
- W2004238966 title "Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics" @default.
- W2004238966 cites W1496843021 @default.
- W2004238966 cites W1560304345 @default.
- W2004238966 cites W1604217211 @default.
- W2004238966 cites W190432982 @default.
- W2004238966 cites W1948894535 @default.
- W2004238966 cites W1965940175 @default.
- W2004238966 cites W1977070772 @default.
- W2004238966 cites W1977236240 @default.
- W2004238966 cites W1983118933 @default.
- W2004238966 cites W1983133139 @default.
- W2004238966 cites W1984921391 @default.
- W2004238966 cites W1986620080 @default.
- W2004238966 cites W1988730368 @default.
- W2004238966 cites W1990567113 @default.
- W2004238966 cites W2003282215 @default.
- W2004238966 cites W2009652756 @default.
- W2004238966 cites W2020751391 @default.
- W2004238966 cites W2024355407 @default.
- W2004238966 cites W2024948293 @default.
- W2004238966 cites W2047069677 @default.
- W2004238966 cites W2048266684 @default.
- W2004238966 cites W2049994834 @default.
- W2004238966 cites W2067172637 @default.
- W2004238966 cites W2068936307 @default.
- W2004238966 cites W2072763411 @default.
- W2004238966 cites W2076226202 @default.
- W2004238966 cites W2076477832 @default.
- W2004238966 cites W2076484723 @default.
- W2004238966 cites W2077009364 @default.
- W2004238966 cites W2079999567 @default.
- W2004238966 cites W2083311377 @default.
- W2004238966 cites W2090828958 @default.
- W2004238966 cites W2095927831 @default.
- W2004238966 cites W2098831733 @default.
- W2004238966 cites W2103809717 @default.
- W2004238966 cites W2113319228 @default.
- W2004238966 cites W2113500539 @default.
- W2004238966 cites W2126957519 @default.
- W2004238966 cites W2130848936 @default.
- W2004238966 cites W2132144498 @default.
- W2004238966 cites W2137984107 @default.
- W2004238966 cites W2141619337 @default.
- W2004238966 cites W2142768458 @default.
- W2004238966 cites W2143578692 @default.
- W2004238966 cites W2147830349 @default.
- W2004238966 cites W2150401511 @default.
- W2004238966 cites W2152770536 @default.
- W2004238966 cites W2154820316 @default.
- W2004238966 cites W2157007129 @default.
- W2004238966 cites W2157180959 @default.
- W2004238966 cites W2159039084 @default.
- W2004238966 cites W2159155203 @default.
- W2004238966 cites W2916950229 @default.
- W2004238966 doi "https://doi.org/10.1186/1471-244x-11-87" @default.
- W2004238966 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3125242" @default.
- W2004238966 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21586165" @default.
- W2004238966 hasPublicationYear "2011" @default.
- W2004238966 type Work @default.
- W2004238966 sameAs 2004238966 @default.
- W2004238966 citedByCount "10" @default.
- W2004238966 countsByYear W20042389662012 @default.
- W2004238966 countsByYear W20042389662013 @default.
- W2004238966 countsByYear W20042389662015 @default.
- W2004238966 countsByYear W20042389662018 @default.
- W2004238966 countsByYear W20042389662020 @default.
- W2004238966 countsByYear W20042389662022 @default.
- W2004238966 crossrefType "journal-article" @default.
- W2004238966 hasAuthorship W2004238966A5011706362 @default.
- W2004238966 hasAuthorship W2004238966A5024756328 @default.
- W2004238966 hasAuthorship W2004238966A5042279631 @default.
- W2004238966 hasAuthorship W2004238966A5085051732 @default.
- W2004238966 hasAuthorship W2004238966A5086273186 @default.
- W2004238966 hasBestOaLocation W20042389661 @default.
- W2004238966 hasConcept C118552586 @default.
- W2004238966 hasConcept C126322002 @default.
- W2004238966 hasConcept C15744967 @default.
- W2004238966 hasConcept C2776412080 @default.
- W2004238966 hasConcept C2776619155 @default.
- W2004238966 hasConcept C2777270317 @default.
- W2004238966 hasConcept C2780057945 @default.
- W2004238966 hasConcept C2780211496 @default.
- W2004238966 hasConcept C2780494398 @default.
- W2004238966 hasConcept C2780634440 @default.
- W2004238966 hasConcept C2780948584 @default.
- W2004238966 hasConcept C513476851 @default.
- W2004238966 hasConcept C71924100 @default.
- W2004238966 hasConceptScore W2004238966C118552586 @default.
- W2004238966 hasConceptScore W2004238966C126322002 @default.
- W2004238966 hasConceptScore W2004238966C15744967 @default.
- W2004238966 hasConceptScore W2004238966C2776412080 @default.